Glenmark Pharmaceuticals USA launches Fingolimod Capsules, 0.5 mg in US
1 November 2022 -

Glenmark Pharmaceuticals Inc USA, a subsidiary of India-based Glenmark Pharmaceuticals, a global pharmaceutical company with a presence across Specialty, Generics and OTC businesses, announced on Monday that it has introduced its Fingolimod Capsules, 0.5 mg, the generic version of Novartis Pharmaceuticals' Gilenya Capsules, 0.5 mg, in the United States.

Sanjeev Krishan, president, Glenmark North America, said: "'We are very pleased to bring to market a lower cost alternative to Gilenya Capsules, 0.5 mg. This launch confirms our commitment to provide quality and affordable pharmaceutical products to patients."

The company's present portfolio includes 176 products approved for distribution in the United States marketplace and 47 ANDA's pending approval with the US FDA. The company says that it also continues to identify and explore external development collaborations to supplement and expedite the growth of its present pipeline and portfolio.